Trump Uses 100% Tariffs to Force Drug Pricing Agreements

President Donald Trump signed an executive order on March 31, 2026, that establishes a new tariff regime for patented pharmaceuticals and their active ingredients. The administration is utilizing these tariffs, which can reach up to 100%, as leverage to secure confidential pricing and manufacturing agreements with both large and small drugmakers.

The policy aims to lower drug prices in the United States and force the onshoring of pharmaceutical production. According to the executive order, the administration deems these actions necessary to address the threatened impairment of the national security posed by imports of pharmaceuticals and pharmaceutical ingredients.

Tariff Structures and Compliance Pathways

The executive order creates three distinct tariff tiers based on a company’s willingness to negotiate pricing and invest in domestic infrastructure.

• Companies that sign a most favored nation pricing deal and are actively building facilities in the U.S. To onshore the production of patented pharmaceuticals and their ingredients will be subject to a 0% tariff.
• Companies that are building U.S. Production projects but have not reached a pricing deal will face a 20% tariff, which is scheduled to increase to 100% in four years.
• Drugmakers that do not reach deals with the administration or commit to onshoring will be hit with a 100% tariff.

A senior administration official indicated that companies have a window of several months to negotiate before the maximum tariffs are implemented. Larger companies have 120 days to reach an agreement, while all other companies have 180 days.

The administration has already begun reaching these agreements. A senior official reported that 17 pricing deals have been reached with major drugmakers, and 13 of those have been signed.

National Security and Trade Strategy

The move represents a strategic shift in the administration’s trade approach. This action follows a Supreme Court decision in 2025 that struck down global levies imposed by the administration, though those previous levies had excluded the pharmaceutical industry.

Administration officials have emphasized the importance of domesticating the medical supply chain to ensure stability. A senior official stated on March 31, 2026, that the goal is to make sure that our drug supply is protected, secure and domestic.

In a separate action taken on March 31, 2026, the administration also modified how tariffs are calculated for imported products containing copper, aluminum, and steel, as well as for raw materials made from those metals.

Broader Trends in Medical Trust

While the administration focuses on the economics and security of drug production, other trends are emerging regarding how patients interact with established medicine. A growing interest in peptides has highlighted a trust gap within the medical community.

Reports indicate that some patients are increasingly favoring unproven treatments over well-established medications, reflecting a shift in confidence toward traditional pharmaceutical offerings.